Regulatory Toxicology and Pharmacology · 2014 · 11 citations · 18 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyPharmacokinetic ModelingToxicokineticsAntibody PharmacokineticsDrug DispositionPhysiologically Based Toxicokinetic ModelingPreclinical Drug EvaluationPreclinical Toxicity TestingToxicology AssessmentClinical Safety EvaluationClinical Toxicity AssessmentEfficacy In Animal ModelsIntravenous ToxicokineticsPharmacokinetic ToxicologySerum Half-lifeToxicokinetic-pharmacodynamic ModelingToxicokinetic-pharmacodynamic Relationships
PEGylated recombinant human endostatin (M2ES) exhibited prolonged serum half-life and enhanced antitumor activity when compared with endostatin. A non-clinical study was performed to evaluate the toxicokinetics and safety of M2ES in rhesus monkeys. After intravenous (IV) infusions of M2ES at a dose level of 3, 10, and 30mg/kg in rhesus monkeys, the concentration-time curves of M2ES were best fitted to a non-compartment model, and area under the curve (AUC) was positively correlated with the dosage. M2ES had a tendency to accumulate in vivo following successive IV infusions. Serum anti-M2ES IgG antibodies were generated quickly during IV administration, and the antibody level in serum did not significantly decrease after four-week recovery period. Animals administered IV infusions twice weekly (M2ES at 10 or 30mg/kg body weight per day) for 3months developed mild or moderate vacuolation of proximal tubule epithelial cell in proximal convoluted tubule of kidney, but this adverse-effect was reversible. In summary, M2ES was well tolerated and did not cause any serious toxicity. These pre-clinical safety data contribute to the initiation of the ongoing clinical study.
18
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth
Michael S. O’Reilly, Thomas Boehm, Yuen Shing et al. · Cell · 1997 · 4.5K citations · Full text
Medicine, Oncology, Pharmacology +11
Akulapalli Sudhakar, Hikaru Sugimoto, Changqing Yang et al. · Proceedings of the National Academy of Sciences · 2003 · 480 citations · Full text
Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin
Hubing Shi, Yujie Huang, Hao Zhou et al. · Blood · 2007 · 246 citations
Medicine, Oncology, Pharmacology +5